Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $54.73 Consensus Price Target from Analysts

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) have been given an average rating of “Buy” by the thirteen analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $54.7273.

XENE has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Wells Fargo & Company boosted their price target on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. upped their price target on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Finally, Royal Bank Of Canada lifted their price objective on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th.

Xenon Pharmaceuticals Stock Down 2.0%

Shares of NASDAQ XENE opened at $42.23 on Friday. The company’s fifty day simple moving average is $42.43 and its 200 day simple moving average is $40.75. The firm has a market cap of $3.26 billion, a PE ratio of -10.86 and a beta of 0.96. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.60.

Insider Activity at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $266,580. The trade was a 86.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 65,302 shares of company stock valued at $2,924,128 over the last three months. 4.07% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Elevation Point Wealth Partners LLC purchased a new stake in shares of Xenon Pharmaceuticals in the second quarter worth about $32,000. Danske Bank A S purchased a new position in Xenon Pharmaceuticals during the third quarter valued at approximately $32,000. Blue Trust Inc. increased its holdings in Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new stake in Xenon Pharmaceuticals in the 4th quarter worth approximately $33,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter worth approximately $39,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.